Campbell Neurosciences Press Releases

trader32176
Posts: 3699
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International and Campbell Neurosciences Announce Preclinical Studies Showing Low Doses of FDA Cleared Immune Stimulant Interleukin-2 Reduces Inflammation Associated Depression in Animal Model

Suicide Prevention Company Rapidly Expanding Pipeline on Immunotherapy of Psychiatric Conditions


https://www.prnewswire.com/news-release ... 92421.html


ELK CITY, Idaho, May 17, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today preclinical data utilizing low doses of the FDA cleared therapeutic interleukin-2 in treatment of inflammation induced depression in an animal model.

The experiments, which are covered in a patent application, demonstrate that low doses of interleukin-2 reduce depressive behavior, which is dependent on a newly identified cellular mechanism.

Given that interleukin-2 at higher doses is approved by the FDA for treatment of melanoma and renal cell cancer, the Company believes that clinical development of this novel approach to depression may possess less regulatory hurdles than other product candidates.

"At Campbell Neurosciences our focus is to create a world in which suicide is a thing of the past," said Kalina O'Connor, President and CEO of Campbell Neurosciences. "The data disclosed today, and the associated patent application are a significant step for our Company in not only detecting suicidal propensities but also having pipeline products for treatment."

Campbell Neurosciences recently announced validation in a clinical trial of its "Campbell Score™" a blood-based test capable of assessing suicidal ideations in a quantitative manner.

"These recent data are an example of the synergistic partnership between Therapeutic Solutions International and Campbell Neurosciences," said Famela Ramos, Vice President of Business Development of Therapeutic Solutions International. "Interleukin-2 is a cancer immunotherapeutic drug that through collaboration we found a novel use in neurology. By continuing to work outside of the box, we strive to rapidly develop novel approaches to the second largest cause of death in young people: suicide."

"Watching the rapid progress of Kalina O'Connor and her team at Campbell Neurosciences is truly inspiring," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "Instead of repositioning potentially dangerous approaches such as ketamine or psychedelic drugs for treatment of depression, the data disclosed today reveals a truly novel research direction to addressing one of the biggest scourges of COVID-19 society: depression. We are excited to watch the clinical translation of this new brain medicine which we call immunotherapy of psychiatry."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE

Therapeutic Solutions International

Related Links


http://www.therapeuticsolutionsint.com
trader32176
Posts: 3699
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Spin-Off Campbell Neurosciences Recruits Global Dealmaker Kenji Funahashi to Advisory Board

Company to Accelerate Commercialization of Suicide Prediction Blood Test Campbell Score


https://www.prnewswire.com/news-release ... 94716.html


ELK CITY, Idaho, May 19, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), stated today its partially owned subsidiary Campbell Neurosciences, the first company to develop a blood based diagnostic test for suicidal ideations, has announced that the internationally renowned transactional lawyer, Mr. Kenji Funahashi, Partner at Wilson Sonsini, has joined its advisory board.

Mr. Funahashi has handled more than $10 billion in financings, mergers and acquisitions, joint ventures, and IPOs, including hundreds of private and public financing transactions for entrepreneurs and investors. He represents technology, life sciences, healthcare, and other growth companies throughout the U.S. and internationally.

"Suicide is the number two cause of death in young people, which despite the increase in new drugs, the rate has been steadily increasing over the past 20 years," said Kenji Funahashi. "I am proud to work with Kalina O'Connor, a visionary who has dedicated her life to defeating suicide and the scientific team she assembled."

Campbell Neurosciences was founded by Kalina O'Connor, and is named after her mother, Kathleen Campbell, who fell a victim to suicide. Kalina's uncle Hugh O'Connor, son of Carroll O'Connor, also was a victim of suicide.

"The depth and breadth of Mr. Funahashi' relations, wisdom, and transactional experiences are difficult to overstate," said Kalina O'Connor, President and CEO of Campbell Neurosciences. "We are honored to join forces with Kenji in tackling this 'silent killer' who has deprived so many of their loved ones."

"We at Therapeutic Solutions International are extremely proud of the accomplishments Ms. O'Connor has been achieving, including completion of two clinical trials significantly ahead of schedule," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "The recruitment of an internationally renowned deal maker like Mr. Funahashi will assist the Company in seeking and forging relationships to bring its diagnostics and therapeutic products to the market in a hyper accelerated timeframe."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

Twitter: @campbellneuros1

SOURCE

Therapeutic Solutions International

Related Links


therapeuticsolutionsint.com
trader32176
Posts: 3699
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Subsidiary Campbell Neurosciences Identifies T Regulatory Cells as a Mechanism of Stem Cell Suppression of Schizophrenia Pathology in an Animal Model

Company Addresses Scientific Studies as it Prepares for FDA Filing to Treat Major Cause of Suicide with Adult Stem Cells


https://www.prnewswire.com/news-release ... 03857.html


ELK CITY, Idaho, June 2, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today a series of experiments, covered by its >1000 claim patent application filed in September 2020, which demonstrate stem cell activity against schizophrenia is associated with T regulatory cell induction.

The experiments demonstrated that mice, which responded to stem cell therapy possessed increased levels of anti-inflammatory cytokines interleukin-4 and interleukin-10, as well as augmented levels of cells expressing FoxP3, a marker characteristic of T regulatory cells. Depletion of T regulatory cells was capable of reducing some of the symptoms of schizophrenia in mice.

"Schizophrenia is one of the biggest predisposing factors to suicide, we at Campbell Neurosciences vow to work diligently and effectively to make schizophrenia a thing of the past," said Kalina O'Connor, President and CEO of Campbell Neuroscience. "I am thankful to our scientific team and collaborators who are working at breakneck speed to obtain as much data as possible so that we may file an investigational new drug (IND) application with the FDA to initiate clinical trials."

"This data strongly supports immunological involvement in schizophrenia, a condition that despite affecting approximately 1% of the population, is still treated in a very empirical manner with little understanding of the molecular mechanisms of the disease, or the currently used treatments," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "We are hoping to use the immunomodulatory properties of adult stem cells to alter several neurological abnormalities that we and others have identified in schizophrenia. To our knowledge, we are the only group utilizing immunology and stem cells to approach this horrific condition."

"This is exciting data and a prime example of the great synergy between our spin-off, Campbell Neurosciences and Therapeutic Solutions," said Timothy Dixon, President and CEO of Therapeutic Solutions International and co-inventor. "By cross-pollinating our work in immunology and neurology, we are making new discoveries at an incredibly rapid pace and we plan on translating these into patents, IND's, and eventually new medicines to treat patients with terrible condition like schizophrenia and cancer."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE


Therapeutic Solutions International

Related Links


therapeuticsolutionsint.com
trader32176
Posts: 3699
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Spinoff Campbell Neurosciences Reports Reduction of Schizophrenia Activity in Mice Subsequent to Administration of Tolerogenic Dendritic Cells

Company Continues to Advance Technologies Described in its >1000 Claim Patent on Cellular Therapy for Schizophrenia


https://www.prnewswire.com/news-release ... 09916.html


ELK CITY, Idaho, June 10, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today that its subsidiary, Campbell Neurosciences, recently obtained data demonstrating that the administration of tolerogenic dendritic cells in an animal model of schizophrenia resulted in suppression of multiple neurological manifestations of the condition. Of great interest was the association between increased numbers of T regulatory cells and therapeutic activity. Previously the Company reported that administration of T regulatory cells are capable of suppressing schizophrenia.

"It is incredible to contemplate that immunological reactions such as the ability of tolerogenic dendritic cells to induce T regulatory cells can be used to treated neurological diseases. The interplay between the brain and the immune system is the foundation of Campbell Neurosciences, and I am very excited to lead the translation of this very relevant animal study into human clinical trials," stated Dr. James Veltmeyer, Chief Medical Officer of the Company.

Campbell Neurosciences was originally founded as a division of Therapeutic Solutions International and subsequently spun off as an independent company, which is focused on ending suicide using immunology and regenerative psychiatry. The company was founded by Kalina O'Connor, the President and CEO of the Company, whose mother, Kathleen O'Connor, and uncle, Hugh O'Connor (son of Carroll O'Connor), were victims of suicide.

"The only way to put an end to this silent epidemic of suicide is to aggressively approach it as a biological disease and not as a choice that people of weak minds make," said Ms. O'Connor. "I have three young kids; suicide is the second largest cause of death in young people. As a daughter of someone who was a victim of suicide, and as a mother now, I feel like not enough work is being done. That is why I am extremely grateful to our investors, our collaborators, and our team that every day is advancing knowledge to the biological causes of suicide."

Campbell Neuroscience's lead product is the Campbell Score, a clinically validated blood test for prediction of suicidal ideation. Additionally, the Company (TSOI) has 13 patent applications filed covering diagnostics and therapeutic solutions.

"Schizophrenia is a very peculiar disease which possesses numerous immunological connections," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "There is much cross-fertilization that occurs between our two companies, especially from the sense that TSOI is focused on using the immune system to kill cancer, whereas Campbell is using the immune system to detect and to alter neuronal activities. Through these interactions we continually develop new ideas, experiments, patents, and ways of interpreting preclinical and clinical data. It is a real pleasure to collaborate with Campbell Neuroscience on this very important life issue."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE


Therapeutic Solutions International

Related Links


https://therapeuticsolutionsint.com/
trader32176
Posts: 3699
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Campbell Neurosciences Spin Off of Therapeutic Solutions Reports Synergistic Reduction of Schizophrenia in Animal Models using Low Dose Naltrexone and T Regulatory Cell Stimulation

Suicide Prevention Company Continues Experimental Validation of its >1000 Claim Patent on Application of Immunotherapy to Schizophrenia


https://www.prnewswire.com/news-release ... 13738.html


ELK CITY, Idaho, June 16, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today new data validating claims in its previously filed patent application demonstrating potent synergy between low dose naltrexone and agents stimulating T regulatory cells.

In one set of experiments, interleukin-2, an FDA cleared cancer immunotherapy drug is combined with low dose naltrexone to potently reduce schizophrenic-like behavior in an animal model of the condition. Naltrexone is a medication approved by the Food and Drug Administration (FDA) to treat both opioid use disorder and alcohol use disorder as a medication-assisted treatment option. Studies also showed that low dose naltrexone synergizes with mesenchymal stem cells and myeloid suppressor cells, both cell types are capable of inducing the generation of T regulatory cells in vivo.

"Schizophrenia is a major cause of suicide and suicidal ideation for which no real treatments exist in patients that are refractory to electroconvulsive therapy," said Kalina O'Connor, President and CEO of Campbell Neurosciences. "We are actively working at refining our various approaches so that we may file an IND with the FDA in the near term."

"From a physician perspective, I am much more comfortable repositioning drugs that have already been demonstrated safe, as opposed to introducing novel and untested compositions of matter in patients," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "The rapid rate of new findings by the Company is based upon a mechanistic-first approach, in which Campbell Scientists first started identifying cellular activities associated with reduction of schizophrenia, and subsequently began testing novel means of modulating the relevant cellular activities."

"The interplay between the immune system and nervous system is fascinating. The fact that immune modulation is associated with reduction in schizophrenic activities strongly supports the notion of the immune-brain interplay," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "In my mind it is not a coincidence that out of all the systems of the body, only the brain and the immune system have the ability to tell between what is "self" and what is "non-self" and also to have memory. We are very excited about the work at Campbell, which will not only teach us how to modulate the brain with the immune system, but also how to modulate the immune system using neurological based approaches. The potency of this is difficult to overstate....imagine if we can generate immune stimulation by administration of select neuropeptides in order to biologically mimic, and amplify, the placebo effect."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE

Therapeutic Solutions International

Related Links


therapeuticsolutionsint.com
trader32176
Posts: 3699
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Spin-Off Campbell Neurosciences Initiates Pilot Implementation of Campbell Score™ with California Concierge Medical & Wellness Inc.

https://www.prnewswire.com/news-release ... 24925.html


ELK CITY, Idaho, July 2, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today medical implementation of its Campbell Score™ blood-based suicide prediction marker in collaboration with the premiere San Diego personalized health center, Concierge Medical & Wellness Inc.

The Campbell Score™ was subject of a clinical trial1 which demonstrated patients with suicidal tendencies have a higher rating on the novel scale2. To the knowledge of the Company, the Campbell Score™ is the only subjective instrument in development capable of assisting psychiatrists in guiding frequency and intensity of their interventions.

"The Campbell Score™ is named after my mother, Kathleen Campbell, who was a victim of suicide. The goal of our Company is to create a world without suicide. The first step in this is quantifying risk of suicide in a scientific and objective manner," said Kalina O'Connor, President and CEO of Campbell Neurosciences. "We are extremely grateful that Chief Medical Officer, Dr. James Veltmeyer, volunteered for us to use his medical practice as the original launching pad for the Campbell Score™. Through initial implementation on a pilot basis, we can work on kinks in a real-life environment while we are concurrently working on launching a pivotal trial to apply for FDA clearance and eventual insurance reimbursement."

"Kalina O'Connor is a true inspiration. It is extremely rare to work with someone who can translate the suffering of a personal tragedy into a company that has a real shot at changing the way suicide is perceived by the medical community," said Dr. James Veltmeyer, Chief Medical Officer of the Company and Owner of California Concierge Medical & Wellness Inc. "I am proud to put my name and reputation behind this completely revolutionary approach to a terrible epidemic which is the number two cause of death in young people."

"At the end of the day, we are all in the field of biomedical sciences because we want to advance science and save lives," said Timothy Dixon, President and CEO of Therapeutic Solutions International and Chairman of Campbell Neurosciences. "It brings great joy to me and our shareholders that this new tool developed by our spin-off company is entering medical practice. I applaud Ms. O'Connor for her perseverance and leadership skills in taking this small step with Dr. Veltmeyer that we hope will be the basis for seeing suicide as a disease and not a choice."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Correlation of Campbell Score With Suicidal Ideation - Full Text View - ClinicalTrials.gov
2 Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Clinical Trial Results for Campbell Score Blood Based Suicide Prediction | BioSpace

ir@tsoimail.com

SOURCE

Therapeutic Solutions International

Related Links


therapeuticsolutionsint.com
trader32176
Posts: 3699
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Spin-Off Campbell Neurosciences Explains Why Suicide is a Disease and How to Predict it in Newly Released Video

https://www.prnewswire.com/news-release ... 27904.html


ELK CITY, Idaho, July 8, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today that its Spin-Off Company, Campbell Neurosciences, released a video presentation describing its position and future directions in relation to diagnosis and prevention of suicide.

The video is available at the Campbell Neurosciences YouTube channel Suicide is a Disease: The Story of Campbell Neurosciences - YouTube







Suicide is the second leading cause of death in young people and is expected to have significantly increased since the beginning of the COVID-19 pandemic. The Company has developed a clinically-validated diagnostic test for suicidal ideations, the Campbell Score™ and a variety of intervention methodologies using regenerative and immune modulatory approaches.

"I am thankful for Howard Leonhardt, a serial inventor and entrepreneur, whose inventions have treated over 500,000 patients in 60 countries, Dr. James Veltmeyer our Chief Medical Officer, and Timothy Dixon, Chief Executive Officer of Therapeutic Solutions International, all of whom are featured in the video," said Kalina O'Connor, President and CEO of Campbell Neurosciences. "I am especially grateful to our numerous scientific collaborators, who believed in my vision of a molecular basis for suicide and worked with our team in making this a reality."

"It has truly been an honor to see the rapid progress Ms. O'Connor has been achieving with her team at Campbell Neurosciences. Progress that included TSOI filing more than 15 patients and licensing 10 of them to Campbell, completing 2 clinical trials, and recruiting top notch key opinion leaders," said Timothy Dixon, Chief Executive Officer of Therapeutic Solutions International. "I truly believe that by working with the brilliant business and scientific minds she has assembled, Ms. O'Connor will accomplish her dream of one day having a world without suicide."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE

Therapeutic Solutions International
trader32176
Posts: 3699
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Announces Titan of Industry Dr. Peter Farrell Joins Advisory Board of its Suicide Prevention Spin-Off Campbell Neurosciences

Founder and Chairman of 40 Billion Dollar Market Cap Company to Accelerate "Science-Based" Approach to Prevention of Suicide

https://www.prnewswire.com/news-release ... 59622.html


ELK CITY, Idaho, Aug. 20, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today that Peter C Farrell, PhD, DSc, AM joined the Advisory Board of its Spin-Off Company Campbell Neurosciences.

Campbell Neurosciences is focused on approaching suicide as a biological disorder and has recently reported positive results on the ability of its in-licensed patent pending blood-based Campbell Score® to predict suicidal ideations1.

"It is with great honor that I welcome Dr. Farrell to the Campbell Neurosciences Advisory Board. Dr. Farrell possesses the rare gift of being very business savvy while also being an acknowledged and well published scientist/engineer. It is rare to find one individual with both traits at such a high level," said Kalina O'Connor President and CEO of Campbell Neurosciences. "I look forward to Dr. Farrell's advice and insight as Campbell Neurosciences continues on its path to developing immunology-based diagnostics and therapeutics for suicidal ideations and actions."

Dr. Farrell is the founder and chairman of the board of ResMed (RMD), a NYSE traded company that changes lives with medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. Dr. Farrell also is Chairman of Arcturus, Inc. (ARCT), a NASDAQ-listed leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Dr. Farrell is on the board of trustees of The Scripps Research Institute, as well as a member of the MIT Dean of Engineering Advisory Board and the Executive Council of the Division of Sleep Medicine at Harvard Medical School, of which he was chair during 2011-2013.

"The story of Campbell Neurosciences is scientifically intriguing, since to my knowledge this is the only company that has successfully used a blood-based immunology marker to explore suicidality as a potential mental disorder," said Dr. Farrell. "I commend Ms. O'Connor for her diligence in creating and obtaining funding for the Company, which was named after her mother, Kathleen Campbell, who was a victim of suicide."

"We at Therapeutic Solutions International are extremely pleased to see Ms. O'Connor take Campbell Neurosciences from what originally was a division founded by our Company to what is now an independent spin-off biotech. She subsequently was successful at fund raising, led completion of clinical trials, and now is attracting internationally renowned business leaders as the Company expands in fulfilling its vision of approaching suicide as a biomedical abnormality as opposed to a selfish choice that people make," said Timothy Dixon, President and CEO of Therapeutic Solutions International and Co-Founder of Campbell. "We will support Campbell Neurosciences and Ms. O'Connor in whatever means necessary to achieve the goal of a world without suicide."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Clinical Trial Results for Campbell Score Blood Based Suicide Prediction | BioSpace

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
Post Reply